HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 9.4 X64_SR12 18JUN21:06:47:1718JUN21:06:47:17 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS IE SASDATA 9.4 X64_SR12 18JUN21:06:47:1718JUN21:06:47:17 Inclusion/Exclusion Criteria Not Met HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000001300000000000000000000 STUDYID Study Identifier DOMAIN Domain Abbreviation USUBJID Unique Subject Identifier  SUBJID Subject Identifier )IESEQ Sequence Number 2IETESTCDInclusion/Exclusion Criterion Short Name :IETEST Inclusion/Exclusion Criterion A IECAT Inclusion/Exclusion Category   IEORRES I/E Criterion Original Result  IESTRESCI/E Criterion Result in Std Format  EPOCH Epoch  IEDTC Date/Time of Collection ( IEDY Study Day of Collection 2 HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 mRNA-1273-P201IEmRNA-1273-P201-US201-1001US2011001AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US201-1003US2011003AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US201-1005US2011005AEXC10 History of chronic smoking (>= 1 cigarette a day) within 1 year of the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US201-1006US2011006AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US201-1015US2011015AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US201-1021US2011021AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US201-1022US2011022AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US201-1024US2011024AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US201-1027US2011027AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US201-1033US2011033AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US201-1034US2011034AEXC15 Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US201-1035US2011035AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US201-1037US2011037AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US201-1045US2011045AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US201-1049US2011049AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US201-1052US2011052AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US201-1053US2011053AEXC22 Positive serology for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) type 1 or 2 antibodies identified at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US201-1054US2011054AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US201-1062US2011062AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US201-1066US2011066AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US201-1071US2011071AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US201-1072US2011072AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US201-1074US2011074AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US201-1075US2011075AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US201-1076US2011076AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US201-1077US2011077AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US201-1078US2011078AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US201-1079US2011079AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US201-1094US2011094AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US201-1096US2011096AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US201-1097US2011097AEXC15 Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US201-1098US2011098AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US201-1099US2011099AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US201-1100US2011100AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-04.mRNA-1273-P201IEmRNA-1273-P201-US201-1101US2011101AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-04.mRNA-1273-P201IEmRNA-1273-P201-US201-1104US2011104AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-08.mRNA-1273-P201IEmRNA-1273-P201-US201-1108US2011108AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-09.mRNA-1273-P201IEmRNA-1273-P201-US201-1111US2011111AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US201-1112US2011112AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US201-1115US2011115AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-12.mRNA-1273-P201IEmRNA-1273-P201-US201-1119US2011119AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-12.mRNA-1273-P201IEmRNA-1273-P201-US201-1119US2011119A INC03 According to the assessment of the investigator, is in good general health and can comply with study procedures. INCLUSIONNNSCREENING 2020-06-12.mRNA-1273-P201IEmRNA-1273-P201-US201-1132US2011132AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US201-1133US2011133AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US201-1134US2011134AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-19.mRNA-1273-P201IEmRNA-1273-P201-US201-1135US2011135AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-19.mRNA-1273-P201IEmRNA-1273-P201-US201-1136US2011136AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-19.mRNA-1273-P201IEmRNA-1273-P201-US201-1140US2011140AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-22.mRNA-1273-P201IEmRNA-1273-P201-US201-1143US2011143AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-23.mRNA-1273-P201IEmRNA-1273-P201-US201-1144US2011144AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-23.mRNA-1273-P201IEmRNA-1273-P201-US201-1146US2011082AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US201-1146US2011146A INC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-24.mRNA-1273-P201IEmRNA-1273-P201-US201-1147US2011147AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-24.mRNA-1273-P201IEmRNA-1273-P201-US201-1148US2011148AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-25.mRNA-1273-P201IEmRNA-1273-P201-US201-1149US2011010AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26"mRNA-1273-P201IEmRNA-1273-P201-US201-1150US2011129AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US201-1150US2011150A EXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-25.mRNA-1273-P201IEmRNA-1273-P201-US201-1151US2011151AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-25.mRNA-1273-P201IEmRNA-1273-P201-US201-1153US2011141AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-22pmRNA-1273-P201IEmRNA-1273-P201-US201-1154US2011002AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US201-1154US2011154A EXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-25.mRNA-1273-P201IEmRNA-1273-P201-US201-1157US2011110AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-11mRNA-1273-P201IEmRNA-1273-P201-US201-1158US2011036AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US201-1158US2011158A EXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-26.mRNA-1273-P201IEmRNA-1273-P201-US201-1160US2011160AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-30.mRNA-1273-P201IEmRNA-1273-P201-US201-1161US2011161AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-07-01.mRNA-1273-P201IEmRNA-1273-P201-US202-1001US2021001AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1002US2021002AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1005US2021005AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1008US2021008AEXC16 Chronic cardiovascular disease EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1009US2021009AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1013US2021013AEXC09 Current use of any inhaled substance (eg, tobacco or cannabis smoke, nicotine vapors) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1013US2021013A EXC10 History of chronic smoking (>= 1 cigarette a day) within 1 year of the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1014US2021014AEXC21 Anticipating the need for immunosuppressive treatment at any time during participation in the study EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1017US2021017AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1025US2021025AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1026US2021026AEXC19 Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1027US2021027AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1028US2021028AEXC19 Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1030US2021030AEXC19 Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1032US2021032AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1033US2021033AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1034US2021034AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1036US2021036AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1037US2021037AEXC16 Chronic cardiovascular disease EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1038US2021038AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1041US2021041AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1048US2021048AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1048US2021048A INC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1049US2021049AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1050US2021050AEXC19 Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1051US2021051AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1052US2021052AINC03 According to the assessment of the investigator, is in good general health and can comply with study procedures. INCLUSIONNNSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1053US2021053AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1054US2021054AEXC16 Chronic cardiovascular disease EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1055US2021055AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1056US2021056AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1057US2021057AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1060US2021060AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1065US2021065AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1066US2021066AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1069US2021069AINC03 According to the assessment of the investigator, is in good general health and can comply with study procedures. INCLUSIONNNSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1071US2021071AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1072US2021072AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1075US2021075AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1077US2021077AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1079US2021079AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1081US2021081AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1083US2021083AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1085US2021085AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1086US2021086AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1087US2021087AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1088US2021088AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1091US2021091AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1091US2021091A EXC09 Current use of any inhaled substance (eg, tobacco or cannabis smoke, nicotine vapors) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1091US2021091A0EXC10 History of chronic smoking (>= 1 cigarette a day) within 1 year of the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1092US2021092AEXC09 Current use of any inhaled substance (eg, tobacco or cannabis smoke, nicotine vapors) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1092US2021092A EXC10 History of chronic smoking (>= 1 cigarette a day) within 1 year of the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1095US2021095AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1097US2021097AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1098US2021098AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1100US2021100AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1102US2021102AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1103US2021103AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1103US2021103A INC03 According to the assessment of the investigator, is in good general health and can comply with study procedures. INCLUSIONNNSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1105US2021105AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1108US2021108AEXC16 Chronic cardiovascular disease EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1109US2021109AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US202-1110US2021110AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US202-1112US2021112AEXC16 Chronic cardiovascular disease EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US202-1113US2021113AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US202-1116US2021116AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US202-1117US2021117AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US202-1118US2021118AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US202-1119US2021119AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US202-1120US2021120AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US202-1122US2021122AEXC15 Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US202-1123US2021123AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US202-1124US2021124AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US202-1125US2021125AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US202-1126US2021126AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US202-1127US2021127AEXC14 Diabetes mellitus EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US202-1128US2021128AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US202-1129US2021129AEXC15 Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US202-1131US2021131AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US202-1132US2021132AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US202-1134US2021134AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US202-1136US2021136AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US202-1139US2021139AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US202-1140US2021140AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-02.mRNA-1273-P201IEmRNA-1273-P201-US202-1141US2021141AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-06-02.mRNA-1273-P201IEmRNA-1273-P201-US202-1142US2021142AEXC20 Received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening Visit. Topical tacrolimus is allowed if not used <=14 days prior to Screening VisitEXCLUSIONYYSCREENING 2020-06-02.mRNA-1273-P201IEmRNA-1273-P201-US202-1143US2021143AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-02.mRNA-1273-P201IEmRNA-1273-P201-US202-1146US2021146AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-02.mRNA-1273-P201IEmRNA-1273-P201-US202-1148US2021148AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-02.mRNA-1273-P201IEmRNA-1273-P201-US202-1149US2021149AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1150US2021150AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1152US2021152AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1153US2021153AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1156US2021156AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1157US2021157AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1158US2021158AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1159US2021159AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1160US2021160AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1163US2021163AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1165US2021165AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1168US2021168AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1169US2021169AINC03 According to the assessment of the investigator, is in good general health and can comply with study procedures. INCLUSIONNNSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1170US2021170AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1171US2021171AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1172US2021172AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US202-1173US2021173AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-04.mRNA-1273-P201IEmRNA-1273-P201-US202-1174US2021174AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-04.mRNA-1273-P201IEmRNA-1273-P201-US202-1176US2021176AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-06-04.mRNA-1273-P201IEmRNA-1273-P201-US202-1177US2021177AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-05.mRNA-1273-P201IEmRNA-1273-P201-US202-1181US2021181AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-05.mRNA-1273-P201IEmRNA-1273-P201-US202-1183US2021183AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-05.mRNA-1273-P201IEmRNA-1273-P201-US202-1184US2021184AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-10.mRNA-1273-P201IEmRNA-1273-P201-US202-1187US2021187AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US202-1191US2021191AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US202-1193US2021193AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-06-12.mRNA-1273-P201IEmRNA-1273-P201-US202-1194US2021194AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-12.mRNA-1273-P201IEmRNA-1273-P201-US202-1195US2021195AEXC16 Chronic cardiovascular disease EXCLUSIONYYSCREENING 2020-06-12.mRNA-1273-P201IEmRNA-1273-P201-US202-1197US2021197AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-06-12.mRNA-1273-P201IEmRNA-1273-P201-US202-1199US2021199AINC03 According to the assessment of the investigator, is in good general health and can comply with study procedures. INCLUSIONNNSCREENING 2020-06-15.mRNA-1273-P201IEmRNA-1273-P201-US202-1202US2021006AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US202-1202US2021202A EXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-16.mRNA-1273-P201IEmRNA-1273-P201-US202-1203US2021203AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-16.mRNA-1273-P201IEmRNA-1273-P201-US202-1204US2021204AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-16.mRNA-1273-P201IEmRNA-1273-P201-US202-1205US2021035AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27mRNA-1273-P201IEmRNA-1273-P201-US202-1206US2021029AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26%mRNA-1273-P201IEmRNA-1273-P201-US202-1207US2021104AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28mRNA-1273-P201IEmRNA-1273-P201-US202-1208US2021044AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27#mRNA-1273-P201IEmRNA-1273-P201-US202-1209US2021046AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1209US2021209A EXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US202-1210US2021042AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US202-1210US2021210A EXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US202-1211US2021010AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26%mRNA-1273-P201IEmRNA-1273-P201-US202-1212US2021212AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US202-1213US2021076AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US202-1213US2021213A INC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US202-1214US2021040AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27mRNA-1273-P201IEmRNA-1273-P201-US202-1215US2021070AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27!mRNA-1273-P201IEmRNA-1273-P201-US202-1216US2021039AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27$mRNA-1273-P201IEmRNA-1273-P201-US202-1217US2021200AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-06-15mRNA-1273-P201IEmRNA-1273-P201-US202-1218US2021106AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28!mRNA-1273-P201IEmRNA-1273-P201-US202-1219US2021024AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26#mRNA-1273-P201IEmRNA-1273-P201-US202-1220US2021016AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26"mRNA-1273-P201IEmRNA-1273-P201-US202-1222US2021023AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-06-12mRNA-1273-P201IEmRNA-1273-P201-US202-1223US2021223AEXC01 Known history of SARS-CoV-2 infection or known exposure to someone with SARS-CoV-2 infection or COVID-19 EXCLUSIONYYSCREENING 2020-06-29.mRNA-1273-P201IEmRNA-1273-P201-US202-1224US2021224AEXC25 Diagnosis of malignancy within previous 10 years (excluding non-melanoma skin cancer) EXCLUSIONYYSCREENING 2020-06-30.mRNA-1273-P201IEmRNA-1273-P201-US202-1227US2021227AEXC22 Positive serology for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) type 1 or 2 antibodies identified at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-07-01.mRNA-1273-P201IEmRNA-1273-P201-US202-1228US2021228AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-07-01.mRNA-1273-P201IEmRNA-1273-P201-US202-1233US2021233AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-07-02.mRNA-1273-P201IEmRNA-1273-P201-US202-1236US2021236AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-07-06.mRNA-1273-P201IEmRNA-1273-P201-US202-1239US2021239AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-07-06.mRNA-1273-P201IEmRNA-1273-P201-US202-1241US2021241AEXC29 Participated in an interventional clinical study within 28 days prior to the Screening Visit (Day 0) or plans to do so while participating in this study. EXCLUSIONYYSCREENING 2020-07-07.mRNA-1273-P201IEmRNA-1273-P201-US203-1003US2031003AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US203-1005US2031005AEXC16 Chronic cardiovascular disease EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US203-1006US2031006AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US203-1007US2031007AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US203-1008US2031008AEXC01 Known history of SARS-CoV-2 infection or known exposure to someone with SARS-CoV-2 infection or COVID-19 EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US203-1010US2031010AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US203-1015US2031015AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US203-1017US2031017AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US203-1018US2031018AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US203-1024US2031024AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US203-1025US2031025AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US203-1028US2031028AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US203-1031US2031031AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US203-1032US2031032AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US203-1034US2031034AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US203-1036US2031036AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US203-1039US2031039AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US203-1044US2031044AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US203-1046US2031046AINC06 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US203-1052US2031052AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US203-1053US2031053AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US203-1054US2031054AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US203-1055US2031055AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US203-1059US2031059AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US203-1061US2031061AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US203-1064US2031064AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US203-1065US2031065AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US203-1067US2031067AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US203-1068US2031068AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US203-1070US2031070AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US203-1075US2031075AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US203-1076US2031076AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US203-1077US2031077AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US203-1078US2031078AEXC10 History of chronic smoking (>= 1 cigarette a day) within 1 year of the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US203-1082US2031082AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-02.mRNA-1273-P201IEmRNA-1273-P201-US203-1083US2031083AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-05.mRNA-1273-P201IEmRNA-1273-P201-US203-1087US2031087AEXC14 Diabetes mellitus EXCLUSIONYYSCREENING 2020-06-08.mRNA-1273-P201IEmRNA-1273-P201-US203-1088US2031088AEXC16 Chronic cardiovascular disease EXCLUSIONYYSCREENING 2020-06-08.mRNA-1273-P201IEmRNA-1273-P201-US203-1090US2031090AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-08.mRNA-1273-P201IEmRNA-1273-P201-US203-1099US2031099AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-09.mRNA-1273-P201IEmRNA-1273-P201-US203-1113US2031113AEXC16 Chronic cardiovascular disease EXCLUSIONYYSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US203-1115US2031115AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US203-1117US2031117AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US203-1118US2031118AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US203-1119US2031119AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US203-1120US2031120AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US203-1123US2031123AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-17.mRNA-1273-P201IEmRNA-1273-P201-US203-1126US2031126AEXC15 Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma) EXCLUSIONYYSCREENING 2020-06-19.mRNA-1273-P201IEmRNA-1273-P201-US203-1127US2031094AEXC28 Has donated >= 450 mL of blood products within 28 days prior to the Screening Visit (Day 0) or plans to donate blood products during the study. EXCLUSIONYYSCREENING 2020-06-09.mRNA-1273-P201IEmRNA-1273-P201-US203-1127US2031127A EXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-22.mRNA-1273-P201IEmRNA-1273-P201-US203-1130US2031130AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-25.mRNA-1273-P201IEmRNA-1273-P201-US203-1132US2031132AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-29.mRNA-1273-P201IEmRNA-1273-P201-US203-1133US2031133AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-07-02.mRNA-1273-P201IEmRNA-1273-P201-US203-1134US2031134AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-07-06.mRNA-1273-P201IEmRNA-1273-P201-US204-1001US2041001AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US204-1004US2041004AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US204-1009US2041009AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US204-1015US2041015AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US204-1017US2041017AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US204-1028US2041028AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US204-1031US2041031AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US204-1032US2041032AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US204-1033US2041033AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US204-1035US2041035AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US204-1037US2041037AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US204-1038US2041038AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US204-1039US2041039AEXC28 Has donated >= 450 mL of blood products within 28 days prior to the Screening Visit (Day 0) or plans to donate blood products during the study. EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US204-1040US2041040AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US204-1044US2041044AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US204-1045US2041045AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US204-1050US2041050AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US204-1052US2041052AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US204-1057US2041057AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US204-1066US2041066AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US204-1067US2041067AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US204-1069US2041069AEXC28 Has donated >= 450 mL of blood products within 28 days prior to the Screening Visit (Day 0) or plans to donate blood products during the study. EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US204-1070US2041070AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US204-1072US2041072AEXC10 History of chronic smoking (>= 1 cigarette a day) within 1 year of the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US204-1081US2041081AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US204-1083US2041083AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US204-1093US2041093AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-08.mRNA-1273-P201IEmRNA-1273-P201-US204-1095US2041095AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-09.mRNA-1273-P201IEmRNA-1273-P201-US204-1099US2041099AEXC16 Chronic cardiovascular disease EXCLUSIONYYSCREENING 2020-06-09.mRNA-1273-P201IEmRNA-1273-P201-US204-1101US2041101AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-10.mRNA-1273-P201IEmRNA-1273-P201-US204-1105US2041105AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-06-10.mRNA-1273-P201IEmRNA-1273-P201-US204-1110US2041110AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US204-1124US2041124AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-12.mRNA-1273-P201IEmRNA-1273-P201-US204-1128US2041128AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-12.mRNA-1273-P201IEmRNA-1273-P201-US204-1129US2041129AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-15.mRNA-1273-P201IEmRNA-1273-P201-US204-1133US2041133AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-15.mRNA-1273-P201IEmRNA-1273-P201-US204-1134US2041134AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-15.mRNA-1273-P201IEmRNA-1273-P201-US204-1135US2041135AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-06-15.mRNA-1273-P201IEmRNA-1273-P201-US204-1143US2041143AEXC22 Positive serology for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) type 1 or 2 antibodies identified at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-16.mRNA-1273-P201IEmRNA-1273-P201-US204-1148US2041148AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-06-17.mRNA-1273-P201IEmRNA-1273-P201-US204-1156US2041156AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-29.mRNA-1273-P201IEmRNA-1273-P201-US204-1157US2041157AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-06-29.mRNA-1273-P201IEmRNA-1273-P201-US204-1159US2041159AEXC19 Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition EXCLUSIONYYSCREENING 2020-06-30.mRNA-1273-P201IEmRNA-1273-P201-US204-1163US2041163AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-07-01.mRNA-1273-P201IEmRNA-1273-P201-US205-1004US2051004AEXC21 Anticipating the need for immunosuppressive treatment at any time during participation in the study EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US205-1005US2051005AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US205-1006US2051006AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US205-1007US2051007AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US205-1014US2051014AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US205-1015US2051015AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US205-1016US2051016AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US205-1021US2051021AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US205-1023US2051023AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US205-1023US2051023A EXC21 Anticipating the need for immunosuppressive treatment at any time during participation in the study EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US205-1037US2051037AEXC11 History of illegal substance use or alcohol abuse within the past 2 years. This does not apply to historical cannabis use that was formerly illegal in participant's state but is legal at Screening. EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US205-1039US2051039AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US205-1041US2051041AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US205-1046US2051046AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US205-1047US2051047AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US205-1056US2051056AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-12.mRNA-1273-P201IEmRNA-1273-P201-US205-1058US2051058AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-15.mRNA-1273-P201IEmRNA-1273-P201-US205-1061US2051061AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-16.mRNA-1273-P201IEmRNA-1273-P201-US205-1062US2051062AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNSCREENING 2020-06-16.mRNA-1273-P201IEmRNA-1273-P201-US205-1065US2051065AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-17.mRNA-1273-P201IEmRNA-1273-P201-US205-1067US2051067AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-06-17.mRNA-1273-P201IEmRNA-1273-P201-US205-1067US2051067A INC03 According to the assessment of the investigator, is in good general health and can comply with study procedures. INCLUSIONNNSCREENING 2020-06-17.mRNA-1273-P201IEmRNA-1273-P201-US205-1076US2051076AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-19.mRNA-1273-P201IEmRNA-1273-P201-US205-1080US2051080AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-22.mRNA-1273-P201IEmRNA-1273-P201-US205-1082US2051082AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-23.mRNA-1273-P201IEmRNA-1273-P201-US205-1083US2051083AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-23.mRNA-1273-P201IEmRNA-1273-P201-US205-1090US2051090AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-25.mRNA-1273-P201IEmRNA-1273-P201-US205-1091US2051091AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-26.mRNA-1273-P201IEmRNA-1273-P201-US206-1002US2061002AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US206-1004US2061004AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US206-1005US2061005AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US206-1005US2061005A EXC22 Positive serology for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) type 1 or 2 antibodies identified at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US206-1012US2061012AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US206-1014US2061014AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US206-1016US2061016AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US206-1017US2061017AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US206-1028US2061028AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-02.mRNA-1273-P201IEmRNA-1273-P201-US206-1029US2061029AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US206-1030US2061030AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US206-1031US2061031AEXC09 Current use of any inhaled substance (eg, tobacco or cannabis smoke, nicotine vapors) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US206-1033US2061033AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US206-1034US2061034AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-05.mRNA-1273-P201IEmRNA-1273-P201-US206-1038US2061038AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-09.mRNA-1273-P201IEmRNA-1273-P201-US206-1039US2061039AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-10.mRNA-1273-P201IEmRNA-1273-P201-US206-1040US2061040AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-10.mRNA-1273-P201IEmRNA-1273-P201-US206-1041US2061041AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-10.mRNA-1273-P201IEmRNA-1273-P201-US206-1042US2061042AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-10.mRNA-1273-P201IEmRNA-1273-P201-US206-1044US2061044AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-10.mRNA-1273-P201IEmRNA-1273-P201-US206-1047US2061047AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US206-1048US2061048AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US206-1049US2061049AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US206-1050US2061050AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-15.mRNA-1273-P201IEmRNA-1273-P201-US206-1052US2061052AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-15.mRNA-1273-P201IEmRNA-1273-P201-US206-1054US2061054AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-16.mRNA-1273-P201IEmRNA-1273-P201-US206-1056US2061056AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-16.mRNA-1273-P201IEmRNA-1273-P201-US206-1058US2061058AINC03 According to the assessment of the investigator, is in good general health and can comply with study procedures. INCLUSIONNNSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US206-1059US2061059AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US206-1060US2061060AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-19.mRNA-1273-P201IEmRNA-1273-P201-US206-1061US2061061AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-19.mRNA-1273-P201IEmRNA-1273-P201-US206-1062US2061062AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-19.mRNA-1273-P201IEmRNA-1273-P201-US206-1065US2061065AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-23.mRNA-1273-P201IEmRNA-1273-P201-US206-1066US2061066AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-23.mRNA-1273-P201IEmRNA-1273-P201-US206-1067US2061067AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-23.mRNA-1273-P201IEmRNA-1273-P201-US206-1069US2061069AEXC15 Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma) EXCLUSIONYYSCREENING 2020-06-24.mRNA-1273-P201IEmRNA-1273-P201-US206-1070US2061070AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-29.mRNA-1273-P201IEmRNA-1273-P201-US206-1071US2061071AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-30.mRNA-1273-P201IEmRNA-1273-P201-US206-1072US2061072AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-07-01.mRNA-1273-P201IEmRNA-1273-P201-US207-1008US2071008AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-25.mRNA-1273-P201IEmRNA-1273-P201-US207-1009US2071009AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-25.mRNA-1273-P201IEmRNA-1273-P201-US207-1010US2071010AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-25.mRNA-1273-P201IEmRNA-1273-P201-US207-1011US2071011AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-25.mRNA-1273-P201IEmRNA-1273-P201-US207-1015US2071015AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-25.mRNA-1273-P201IEmRNA-1273-P201-US207-1018US2071018AEXC09 Current use of any inhaled substance (eg, tobacco or cannabis smoke, nicotine vapors) EXCLUSIONYYSCREENING 2020-05-25.mRNA-1273-P201IEmRNA-1273-P201-US207-1019US2071019AEXC14 Diabetes mellitus EXCLUSIONYYSCREENING 2020-05-25.mRNA-1273-P201IEmRNA-1273-P201-US207-1020US2071020AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-25.mRNA-1273-P201IEmRNA-1273-P201-US207-1021US2071021AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-25.mRNA-1273-P201IEmRNA-1273-P201-US207-1027US2071027AEXC22 Positive serology for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) type 1 or 2 antibodies identified at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US207-1035US2071035AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US207-1045US2071045AEXC19 Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US207-1053US2071053AEXC29 Participated in an interventional clinical study within 28 days prior to the Screening Visit (Day 0) or plans to do so while participating in this study. EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US207-1055US2071055AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US207-1056US2071056AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US207-1061US2071061AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US207-1076US2071076AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US207-1083US2071057AEXC16 Chronic cardiovascular disease EXCLUSIONYYSCREENING 2020-05-26mRNA-1273-P201IEmRNA-1273-P201-US207-1088US2071052AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29mRNA-1273-P201IEmRNA-1273-P201-US207-1092US2071092AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-19pmRNA-1273-P201IEmRNA-1273-P201-US207-1099US2071099AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-24mRNA-1273-P201IEmRNA-1273-P201-US208-1006US2081006AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-05-26.mRNA-1273-P201IEmRNA-1273-P201-US208-1008US2081008AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US208-1010US2081010AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US208-1012US2081012AEXC14 Diabetes mellitus EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US208-1013US2081013AEXC19 Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition EXCLUSIONYYSCREENING 2020-05-27.mRNA-1273-P201IEmRNA-1273-P201-US208-1016US2081016AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-27PmRNA-1273-P201IEmRNA-1273-P201-US208-1018US2081018AEXC16 Chronic cardiovascular disease EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US208-1018US2081018A EXC25 Diagnosis of malignancy within previous 10 years (excluding non-melanoma skin cancer) EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US208-1021US2081021AEXC16 Chronic cardiovascular disease EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US208-1022US2081022AEXC20 Received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening Visit. Topical tacrolimus is allowed if not used <=14 days prior to Screening VisitEXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US208-1024US2081024AEXC11 History of illegal substance use or alcohol abuse within the past 2 years. This does not apply to historical cannabis use that was formerly illegal in participant's state but is legal at Screening. EXCLUSIONYYSCREENING 2020-05-28.mRNA-1273-P201IEmRNA-1273-P201-US208-1027US2081027AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US208-1031US2081031AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US208-1032US2081032AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US208-1034US2081034AEXC08 Is a healthcare worker or a member of an emergency response team. EXCLUSIONYYSCREENING 2020-05-29.mRNA-1273-P201IEmRNA-1273-P201-US208-1040US2081040AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US208-1043US2081043AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US208-1044US2081044AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-01.mRNA-1273-P201IEmRNA-1273-P201-US208-1047US2081047AEXC19 Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition EXCLUSIONYYSCREENING 2020-06-02.mRNA-1273-P201IEmRNA-1273-P201-US208-1047US2081047A EXC20 Received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening Visit. Topical tacrolimus is allowed if not used <=14 days prior to Screening VisitEXCLUSIONYYSCREENING 2020-06-02.mRNA-1273-P201IEmRNA-1273-P201-US208-1048US2081048AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-02.mRNA-1273-P201IEmRNA-1273-P201-US208-1050US2081050AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-02.mRNA-1273-P201IEmRNA-1273-P201-US208-1053US2081053AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US208-1055US2081055AEXC09 Current use of any inhaled substance (eg, tobacco or cannabis smoke, nicotine vapors) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US208-1056US2081056AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-03.mRNA-1273-P201IEmRNA-1273-P201-US208-1060US2081060AEXC11 History of illegal substance use or alcohol abuse within the past 2 years. This does not apply to historical cannabis use that was formerly illegal in participant's state but is legal at Screening. EXCLUSIONYYSCREENING 2020-06-04.mRNA-1273-P201IEmRNA-1273-P201-US208-1061US2081061AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-04.mRNA-1273-P201IEmRNA-1273-P201-US208-1067US2081067AEXC19 Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition EXCLUSIONYYSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US208-1068US2081068AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNSCREENING 2020-06-11.mRNA-1273-P201IEmRNA-1273-P201-US208-1074US2081074AEXC23 History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine EXCLUSIONYYSCREENING 2020-06-15.mRNA-1273-P201IEmRNA-1273-P201-US208-1078US2081078AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-16.mRNA-1273-P201IEmRNA-1273-P201-US208-1078US2081078A EXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-16.mRNA-1273-P201IEmRNA-1273-P201-US208-1079US2081079AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-17.mRNA-1273-P201IEmRNA-1273-P201-US208-1082US2081082AEXC14 Diabetes mellitus EXCLUSIONYYSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US208-1083US2081083AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US208-1084US2081084AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US208-1086US2081086AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US208-1089US2081089AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-18.mRNA-1273-P201IEmRNA-1273-P201-US208-1094US2081094AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-19.mRNA-1273-P201IEmRNA-1273-P201-US208-1095US2081095AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-19.mRNA-1273-P201IEmRNA-1273-P201-US208-1096US2081096AEXC19 Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition EXCLUSIONYYSCREENING 2020-06-19.mRNA-1273-P201IEmRNA-1273-P201-US208-1098US2081098AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-22.mRNA-1273-P201IEmRNA-1273-P201-US208-1101US2081101AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-22.mRNA-1273-P201IEmRNA-1273-P201-US208-1102US2081102AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-22.mRNA-1273-P201IEmRNA-1273-P201-US208-1104US2081104AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-23mRNA-1273-P201IEmRNA-1273-P201-US208-1105US2081105AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-23.mRNA-1273-P201IEmRNA-1273-P201-US208-1106US2081106AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-23.mRNA-1273-P201IEmRNA-1273-P201-US208-1107US2081107AEXC15 Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma) EXCLUSIONYYSCREENING 2020-06-23.mRNA-1273-P201IEmRNA-1273-P201-US208-1108US2081108AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-23mRNA-1273-P201IEmRNA-1273-P201-US208-1109US2081109AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-23.mRNA-1273-P201IEmRNA-1273-P201-US208-1111US2081111AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-06-24.mRNA-1273-P201IEmRNA-1273-P201-US208-1114US2081114AEXC15 Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma) EXCLUSIONYYSCREENING 2020-06-24.mRNA-1273-P201IEmRNA-1273-P201-US208-1115US2081115AINC04 Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0) INCLUSIONNNSCREENING 2020-06-24.mRNA-1273-P201IEmRNA-1273-P201-US208-1122US2081122AEXC07 Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment. EXCLUSIONYYSCREENING 2020-06-25.mRNA-1273-P201IEmRNA-1273-P201-US208-1124US2081124AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-25.mRNA-1273-P201IEmRNA-1273-P201-US208-1126US2081126AEXC25 Diagnosis of malignancy within previous 10 years (excluding non-melanoma skin cancer) EXCLUSIONYYSCREENING 2020-06-25.mRNA-1273-P201IEmRNA-1273-P201-US208-1127US2081127AEXC12 Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-25.mRNA-1273-P201IEmRNA-1273-P201-US208-1128US2081128AEXC19 Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition EXCLUSIONYYSCREENING 2020-06-25.mRNA-1273-P201IEmRNA-1273-P201-US208-1130US2081130AEXC18 Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0) EXCLUSIONYYSCREENING 2020-06-25.